Navitas is embarking on a strategic transformation. Navitas 2.0 will pivot away from the mobile market and toward AI data ...
Shares of Mersana Therapeutics have seen their consensus analyst price target increase from $28.29 to $33.20 per share. This reflects a significant boost in confidence following a major acquisition ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback